How big is Verve Therapeutics, Inc.?

As of Jun 18, Verve Therapeutics, Inc. has a market capitalization of 1,015.98 million and reported net sales of 59.62 million with a net profit of -180.99 million over the latest four quarters. Shareholder's funds are 493.40 million, and total assets amount to 647.39 million.

As of Jun 18, Verve Therapeutics, Inc. has a market capitalization of 1,015.98 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 59.62 million, while the sum of net profit for the same period is -180.99 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 493.40 million, and total assets amount to 647.39 million.

What does Verve Therapeutics, Inc. do?

Verve Therapeutics, Inc. is a micro-cap biotechnology company focused on pharmaceuticals, with recent net sales of $33 million and a net loss of $31 million. It has a market cap of approximately $1.02 billion and does not pay dividends.

Overview:<BR>Verve Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 33 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -31 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,015.98 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.03 <BR>Return on Equity: -38.58% <BR>Price to Book: 2.15<BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Verve Therapeutics, Inc.?

Is Verve Therapeutics, Inc. overvalued or undervalued?

As of March 2, 2023, Verve Therapeutics, Inc. is considered risky and overvalued due to negative financial metrics, despite a strong year-to-date return of 97.34%, while its long-term performance remains poor with a three-year return of -63.64%.

As of 2 March 2023, the valuation grade for Verve Therapeutics, Inc. has moved from does not qualify to risky, indicating a higher level of uncertainty regarding its valuation. The company appears to be overvalued given its negative financial metrics, including a Price to Book Value of 1.17, an EV to Sales ratio of 1.12, and a troubling ROE of -38.58%. Comparatively, peers such as ADMA Biologics, Inc. have a fair valuation with a P/E of 18.56, while Kymera Therapeutics, Inc. shows a risky valuation with a P/E of -11.23, highlighting the challenges Verve faces in the market.<BR><BR>In terms of recent performance, Verve Therapeutics has outperformed the S&P 500 with a year-to-date return of 97.34% compared to the index's 12.22%, although it has struggled over the longer term with a three-year return of -63.64% versus the S&P 500's 70.41%. This mixed performance further complicates the valuation narrative, suggesting that while there may be short-term gains, the overall financial health and valuation metrics indicate that the stock is overvalued.

Is Verve Therapeutics, Inc. technically bullish or bearish?

As of July 1, 2025, Verve Therapeutics, Inc. shows a mildly bullish technical trend with strong year-to-date performance of 97.34%, despite mixed indicators and significant underperformance over the past three years.

As of 1 July 2025, the technical trend for Verve Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum. However, the RSI readings are bearish for both weekly and monthly periods, suggesting weakness in price strength. The Bollinger Bands are bullish weekly and mildly bullish monthly, supporting a positive outlook. Daily moving averages are bullish, and the OBV is bullish for both weekly and monthly periods, indicating accumulation. Conversely, the KST shows a bullish weekly but bearish monthly stance, and Dow Theory indicates a mildly bearish weekly trend with no trend monthly.<BR><BR>In terms of performance, Verve Therapeutics has outperformed the S&P 500 year-to-date with a return of 97.34% compared to 12.22%, and over the past year with a return of 57.2% against 17.14%. However, it has significantly underperformed over the 3-year period with a return of -63.64% compared to the S&P 500's 70.41%. Overall, the current technical stance is mildly bullish, driven by mixed indicators but strong year-to-date performance.